Table 1.
Baseline characteristics of 128 patients with pulmonary arterial hypertension
| All subjects (n=128) | ||
|---|---|---|
| Characteristic | Mean ± SD | n (%) |
| Age (years) | 50 ± 14 | |
| Sex | ||
| Female | 95 (74) | |
| Race/Ethnicity | ||
| White, non-Hispanic | 80 (63) | |
| Black | 9 (7) | |
| Hispanic | 19 (15) | |
| Asian | 14 (11) | |
| Other | 6 (5) | |
| Etiology of pulmonary hypertension | ||
| Idiopathic pulmonary arterial hypertension | 50 (39) | |
| Associated pulmonary arterial hypertension | ||
| Connective tissue diseases | 36 (28) | |
| Congenital heart diseases | 3 (2) | |
| Portal hypertension | 16 (13) | |
| HIV infection | 6 (5) | |
| Drug- and toxin-induced | 11 (9) | |
| Other | 6 (5) | |
| Right heart catheterization data | ||
| Mean right atrial pressure (mmHg)* | 11 ± 8 | |
| Mean pulmonary artery pressure (mmHg) | 50 ± 13 | |
| Mean pulmonary capillary wedge pressure (mmHg) | 9.8 ± 4.0 | |
| Cardiac index (L/min·m2)* | 2.4 ± 0.9 | |
| Pulmonary vascular resistance (dyne·sec·cm−5)* | 886 ± 464 | |
| WHO functional class | ||
| Class I | 8 (6) | |
| Class II | 45 (35) | |
| Class III | 66 (52) | |
| Class IV | 9 (7) | |
| 6-minute walk test† | ||
| 6-minute walk distance (m) | 348 ± 115 | |
| Borg dyspnea index, post-walk | 2.7 ± 2.0 | |
| Medications | ||
| Intravenous or subcutaneous prostacyclin infusion | 49 (38) | |
| Inhaled prostacyclin | 4 (3) | |
| Oral endothelin receptor antagonist | 82 (64) | |
| Oral phosphodiesterase-5 inhibitor | 41 (32) | |
WHO: World Health Organization
*
Missing for 7 subjects
†
Missing for 3 subjects